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Background: Acetate supplementation reduces neuroglia activation and pro-inflammatory cytokine expression in
rat models of neuroinflammation and Lyme neuroborreliosis. Because single-dose glyceryl triacetate (GTA) treatment
increases brain phosphocreatine and reduces brain AMP levels, we postulate that GTA modulates adenosine
metabolizing enzymes and receptors, which may be a possible mechanism to reduce neuroinflammation.
Methods: To test this hypothesis, we quantified the ability of GTA to alter brain levels of ecto-5’-nucleotidase
(CD73), adenosine kinase (AK), and adenosine A2A receptor using western blot analysis and CD73 activity by
measuring the rate of AMP hydrolysis. Neuroinflammation was induced by continuous bacterial lipopolysaccharide
(LPS) infusion in the fourth ventricle of the brain for 14 and 28 days. Three treatment strategies were employed,
one and two where rats received prophylactic GTA through oral gavage with LPS infusion for 14 or 28 days. In
the third treatment regimen, an interventional strategy was used where rats were subjected to 28 days of
neuroinflammation, and GTA treatment was started on day 14 following the start of the LPS infusion.
Results: We found that rats subjected to neuroinflammation for 28 days had a 28% reduction in CD73 levels and a
43% increase in AK levels that was reversed with prophylactic acetate supplementation. CD73 activity in these rats
was increased by 46% with the 28-day GTA treatment compared to the water-treated rats. Rats subjected to
neuroinflammation for 14 days showed a 50% increase in levels of the adenosine A2A receptor, which was
prevented with prophylactic acetate supplementation. Interventional GTA therapy, beginning on day 14 following
the induction of neuroinflammation, resulted in a 67% increase in CD73 levels and a 155% increase in adenosine
A2A receptor levels.
Conclusion: These results support the hypothesis that acetate supplementation can modulate brain CD73, AK and
adenosine A2A receptor levels, and possibly influence purinergic signaling.
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In the central nervous system (CNS), adenosine is a po-
tent neuromodulator that regulates sleep, arousal, neur-
onal excitability, cerebral blood flow and inflammation
[1,2]. Under pathological events or increased metabolic
demand, adenosine triphosphate (ATP) metabolism and
adenosine levels increase with a decrease in the energy
charge ratio ((ATP + 0.5*ADP)/(ATP +ADP +AMP)) [3].
Adenosine is described as a ‘retaliatory metabolite’ [4]
since it inhibits high energy utilizing processes, reduces
the cellular metabolic demand, and restores cellular
energy levels. Both adenosine and ATP are ubiquitously
present in most organs and tissues and have an important
signaling role in inflammation [2,5,6]. Thus, adenosine
serves as a link between cellular metabolism and inflam-
matory signaling.
Adenosine modulates brain activity by binding to
G-protein coupled purinergic P1 or adenosine (A1, A2A,
A2B, and A3) receptors [7]. The CNS effects of adenosine
are primarily mediated by inhibitory A1 and stimulatory
A2A receptors [8]. Activation of A1 receptors inhibits
neuronal excitability by reducing excitatory neurotrans-
mitter release and offers neuroprotection [1]. While acti-
vation of peripheral A2A receptors reduces inflammation,
central A2A receptor activation increases glutamate out-
flow and neuroinflammation [9-11]. Adenosine can be
formed both inside as well as outside the cell and distinct
cell-specific mechanisms for the elevation of extracellular
adenosine levels exist [12]. Under conditions of hypoxia,
ischemia, inflammation, nerve stimulation or stress, astro-
cytes release ATP, which is enzymatically metabolized to
adenosine [13]. The rate limiting enzyme in this process is
ecto-5’-nucleotidase (CD73) [14]. Adenosine catabolism,
on the other hand, is controlled by two enzymes: adeno-
sine deaminase and adenosine kinase (AK). Adenosine de-
aminase converts adenosine to inosine, which is typically
negligible in the central nervous system, although this
may change under pathological conditions [2]. Adenosine
kinase converts adenosine to AMP following its uptake
into the cell via nucleoside transporters [15]. Because
adenosine can influence neuronal activity and mediate
neuroinflammation, being able to modulate adenosine
levels or the receptors involved in purinergic signaling has
broad therapeutic potential [16].
A reproducible model of neuroinflammation is gene-
rated in rats by the infusion of the bacterial endotoxin
lipopolysaccharide (LPS) directly into the fourth ventricle
of the brain [17]. In brain, LPS binds to the TLR4/CD14/
MD-2 receptor complex [18] that activates neuroglia,
reduces cholinergic cell immunoreactivity [19], and in-
creases the expression of the pro-inflammatory cytokine
interleukin (IL)-1β [20]. Acetate supplementation, induced
with glyceryl triacetate (GTA, 6 g/kg, by oral gavage) re-
duces LPS-induced neuroglial activation [19,21], IL-1βlevels [20], and loss of cholinergic immunoreactivity [19].
Glyceryl triacetate is an effective treatment in rat models
of Canavan’s disease [22] and traumatic brain injury [23],
possesses growth-arresting properties [24] and is shown to
be safe and well tolerated in human trials for Canavan’s
disease [25]. Oral administration of GTA increase rat
plasma acetate by 100-fold and brain acetyl-CoA levels by
2.2-fold compared to water treated rats [19]. Increase in
acetyl-CoA metabolism further increases brain energy
stores, reduces AMP levels [26] and increases acetylation
of nuclear histones [20,27], which is associated with
attenuation of pro-inflammatory cytokine release [20].
In microglia and astrocyte cell cultures, acetate reverses
LPS-induced hypoacetylation of histones, attenuates
pro-inflammatory cytokines, increases anti-inflamma-
tory cytokine expression, reduces nuclear factor-κB and
mitogen-activated protein kinase mediated signaling,
and reduces prostaglandin E2 and cyclooxygenase 1 and
2 levels [28-30].
Based on this data, we postulated that acetate supple-
mentation modulates the levels of adenosine metabolizing
enzymes and adenosine receptors, which may be a
possible mechanism by which GTA exerts its anti-inflam-
matory and neuroprotective effects. To begin to test this
hypothesis, we quantified the ability of GTA to alter brain
levels and activity of CD73, and the levels of AK and
adenosine A2A receptors. We also examined how protein
levels and activity differed using both prophylactic and
interventional GTA treatment strategies. Prophylactic
acetate supplementation prevented the LPS-induced re-
duction of brain CD73, increased CD73 activity, and pre-
vented the LPS-induced increase of AK and A2A receptor
levels. Interventional GTA treatment increased CD73
similar to the prophylactic treatment, but reduced CD73
activity. Furthermore, in contrast to the prophylactic treat-
ment, interventional GTA increased A2A receptor levels
compared to the water-treated controls. These data
support the hypothesis that acetate supplementation can
modulate adenosine metabolizing enzymes and A2A re-
ceptor expression levels in the brain and possibly enhance
the effects of endogenous adenosine.
Methods
Reagents
Glyceryl triacetate, buffer reagents, β-glycerophosphate,
erythro-9-(2-hydroxy-3-nonyl) adenine, α, β-methylenea-
denosine 5’-diphosphate, and 2-mercaptoethanol were
purchased from Sigma (Sigma, St. Louis, MO, USA). A
mouse anti-human CD73 antibody and a horseradish
peroxidase (HRP)-conjugated goat anti-mouse IgG anti-
body were obtained from AbD Serotec (AbD Serotec,
Raleigh, NC, USA). A HRP-conjugated goat anti-mouse IgG
antibody was purchased from Jackson ImmunoResearch
(Jackson ImmunoResearch, Westgrove, PA, USA). A mouse
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Upstate (Upstate, Billerica, MA, USA). A goat anti-adeno-
sine kinase antibody, mouse anti-α tubulin antibody,
HRP-conjugated donkey anti-goat IgG antibody, and
HRP-conjugated goat anti-mouse IgM antibody were
obtained from Santa Cruz Biotechnology (Santa Cruz
Biotechnology, Santa Cruz, CA, USA). Absolute ethanol
was from Pharmco (Pharmco, Brookfield, CT, USA).Animal studies
This study was conducted in accordance with the NIH
Guidelines for the Care and Use of Laboratory Animals
(NIH Publication No. 80-23) under an approved University
protocol using male Sprague-Dawley rats (Charles River,
Wilmington, MA, USA). All rats were allowed to acclimate
in our facility for at least seven days prior to inclusion in
the study. The surgical implantation of cannulas and
the induction of neuroinflammation were performed as
described previously [19]. A solution of artificial cerebro-
spinal fluid (aCSF) or LPS (20.0 ng/μL, E coli, 055:B5,
Sigma, St. Louis, MO, USA) dissolved in aCSF (Harvard
Apparatus, Holliston, MA, USA) was infused continually
at a rate of 0.25 μL/hr via the osmotic mini-pump for a
period of 14 or 28 days [31,32]. The rats were divided into
three separate experiments: a 14- and 28-day prophylactic
treatment study, and a 28-day interventional treatment
study. During the 14- and 28-day prophylactic treatment
studies, rats were treated daily with water or glyceryl
triacetate (GTA) at a dose of 6 g/kg by oral gavage. In the
28-day interventional study, rats did not begin receiving
daily doses of either water or GTA until 14 days after the
start of the LPS infusion. Interventional treatment was
started on day 14 due to neuroglia activation being signifi-
cantly elevated above controls at this time [17].Extraction of rat brain tissue
Rats were anesthetized with isoflurane, euthanized by
decapitation, and then the brains were removed and dis-
sected anterior to the middle carotid artery in the cor-
onal plane [32]. The postmortem interval for the sample
extraction did not exceed 1.5 min. The dissected brains
were placed in a tube containing 3 mL of ice cold ex-
traction buffer (50 mM Tris buffer (pH 7.4) containing
150 mM sodium chloride, 1 mM EGTA, 1 mM sodium
orthovanadate, 5 mM zinc chloride, 100 mM sodium
fluoride, 1 mM PMSF, one complete, EDTA-free tablet
(Roche Applied Science, Indianapolis, IN, USA) per
50 mL, and 0.1% Igepal CA-630). The sample was
allowed to sit on ice for 10 min, then homogenized using
probe sonication. Homogenized samples were centri-
fuged at 4°C for 20 min at 4,500 x g and the cytosolic
portion was aliquotted into small volumes and stored
at -80°C until use.Western blot analysis
Samples were prepared by boiling in loading buffer
composed of 95% Laemmli sample buffer containing
5% 2-mercaptoethanol. The separation was performed
on 50 μg of protein using a 15% Tris-HCl gel with an
electrophoresis separation of 100 volts for 135 min.
The protein was transferred onto a 0.45 μm nitrocel-
lulose membrane at 100 volts for 90 min in ice. Pri-
mary antibodies against CD73 (1:1,000 dilution), A2AR
(1:1000 dilution), adenosine kinase (1:200 dilution),
and α-tubulin (1:1,500 dilution) were prepared in
20 mM Tris buffer, pH 7.4, containing 150 mM NaCl,
0.05% Tween 20 (TTBS), and 5% nonfat dried milk.
The nitrocellulose membranes were incubated with pri-
mary antibody overnight at 4°C, then incubated with
HRP-linked secondary antibody for 90 min at room
temperature. Secondary antibodies goat anti-mouse
IgG (1:20,000 dilution), goat anti-mouse IgG (1:10,000
dilution), donkey anti-goat IgG (1:10,000 dilution), and
goat anti-mouse IgM (1:10,000 dilution) (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) were prepared in
TTBS buffer. Protein bands were detected using either
SuperSignal™ West Pico or West Femto Chemilumines-
cent Substrates (Pierce, Rockford, IL, USA) and ana-
lyzed in a UVP Bioimaging System equipped with
VisionWorks™ imaging software (version 4.5, Upland,
CA, USA, www.UVP.com). Protein concentration was
measured using the Bradford assay [33]. Optical dens-
ities of the proteins of interest are normalized to the
optical density of the loading control α-tubulin and all
the western blot data are expressed as percentage over
controls.
Ecto-5’-nucleotidase activity
Sample brain extracts were diluted in ice cold assay buf-
fer (50 mM Tris buffer (pH 7.4 at 37°C) containing
20 mM β-glycerophosphate and 20 μM erythro-9-(2-hy-
droxy-3-nonyl) adenine) to a protein concentration of
3.33 μg/μL. Each sample (500 μg protein) was assayed
in duplicate, with one assay containing 400 μM α,
β-methylene adenosine 5’-diphosphate (AMPCP) in the
buffer, as a control to inhibit the activity of CD73, and
the other without AMPCP. Samples were pre-incubated
at 37°C for 10 min, and the assay was started by adding
1 mM AMP and incubating for 30 min at 37°C. The re-
action was stopped with 3 M perchloric acid and placed
on ice before being centrifuged at 18,100 × g for 5 min
at 4°C. The adenosine formed as a result of AMP break-
down by CD73 was then converted into its fluorescent
derivative and quantified using HPLC with fluorescence
detection as described [34]. Adenosine levels from the
control reaction were subtracted from the experimental
reaction to calculate CD73 activity in units of nmol
adenosine/mg protein/min.
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When comparing two groups, an unpaired t-test with a
two-tailed P value was used to calculate statistical differ-
ences using GraphPad InStat statistical software (Version
3.10, Graph Pad Software, Inc., San Diego, CA, USA,
www.graphpad.com). When comparing more than two
groups, a One Way ANOVA with a Tukey’s post-hoc test
was performed using the same statistical software. All re-
sults are expressed as means ± SD with significance set at
P ≤0.05.
Results
To test the hypothesis that acetate supplementation
modulates brain adenosine metabolizing enzymes (CD73
and AK) and adenosine A2A receptor levels, we mea-
sured the levels of these proteins and the activity of
CD73 in three parallel studies. In studies one and two,
rats were subject to neuroinflammation for either 14 or
28 days and received prophylactic acetate supplementa-
tion throughout the duration of the experiment. A third
study was performed in which a group of rats were sub-
jected to 28 days of neuroinflammation, and acetate
supplementation was started interventionally on day 14
following the start of the LPS infusion.
Fourteen day prophylactic acetate supplementation
We measured the levels of CD73, AK, and A2A receptor
and the activity of CD73 in rats after a 14-day study
period. In this study, there were three groups of rats.
Group one received sham surgery with aCSF infusion and
oral water which served as the control group (n = 6),
group two received a LPS infusion dissolved in aCSF with
oral water (n = 12), and group three received LPS and
were treated with daily oral doses of GTA (6 g/kg body
weight) (n = 6). Protein bands for CD73, AK, A2AR, and α-
tubulin corresponding to molecular weights 68, 48, 45,
and 55 kDa respectively, were quantified using western
blot analysis (Figures 1A, 2A, and 3A). We found that LPS
significantly reduced CD73 levels by 38%, while rats that
received LPS plus GTA did not differ from controls
(95% ± 11) (Figure 1B). Since CD73 is the rate-limiting
enzyme for adenosine formation [14] and changes in its
activity are observed in inflammatory conditions [35], we
measured CD73 activity in these samples. The activity of
CD73 did not significantly differ between control and rats
subjected to neuroinflammation. However, rats receiving
LPS plus GTA had a significant increase in activity by
31% compared to controls and rats subjected to LPS
(Figure 1C). Further, no significant differences in AK levels
were observed between the groups (Figure 1D). Based on
these data, we measured A2A receptor levels and found
that LPS infusion causes a significant increase by 50%
compared to controls, while acetate supplementation pre-
vented the LPS-induced increase leaving A2A receptor atcontrol levels (Figure 1E). These results demonstrate that
prophylactic acetate supplementation has the capacity to
prevent LPS-induced changes in CD73 and A2A receptor
levels, and is also able to increase CD73 activity. Although
it is not clear whether acetate supplementation achieves
an increase in CD73 activity through changes in gene ex-
pression or enzyme modification, both may be involved.
These data do, however, suggest that acetate supplementa-
tion can modulate adenosine metabolizing enzymes and
A2A receptor levels.
Twenty-eight day prophylactic acetate supplementation
A 28-day study was performed to examine the long-term
effect of acetate supplementation on brain adenosine
metabolizing enzymes (CD73 and AK) and A2A receptor
levels. The infusion and treatment groups were identical
to those described above except that the GTA treatment
and LPS infusion were continued for a total of 28 days. In
this study, we found that LPS significantly reduced CD73
levels by 28% of controls, which was not evident in rats
that received acetate supplementation (Figure 2B). There
was no difference in CD73 activity between controls and
rats subjected to neuroinflammation, but LPS-treated rats
receiving acetate supplementation showed a significant
increase in activity (46%) compared to controls and rats
subjected to neuroinflammation (Figure 2C). Twenty
eight-day LPS infusion resulted in a significant increase in
AK levels (43%) compared to control rats. We found no
change in AK levels in rats subjected to neuroinflam-
mation and treated with prophylactic acetate supplemen-
tation (Figure 2D). No difference in A2A receptor levels
was observed between groups (Figure 2E). These results
demonstrate that long-term prophylactic acetate supple-
mentation is able to prevent LPS-induced changes in
CD73 and AK levels, and increase CD73 activity using a
28-day prophylactic treatment strategy. Collectively, these
studies suggest that neuroinflammation modulates adeno-
sine metabolizing enzymes, which can be prevented with
prophylactic acetate supplementation.
Interventional acetate supplementation
The effect of interventional acetate supplementation
(starting at 14 days post-LPS infusion until the 28th day of
LPS infusion) on adenosine metabolizing enzymes (CD73
and AK) and A2A receptor levels was examined. Treat-
ment with GTA was begun on day 14 because this is the
earliest time when neuroglia activation, based on signifi-
cant morphological changes in astrocytes and microglia,
has been documented [17] in this model. However, the in-
flammatory signaling starts as early as 6 days following
LPS infusion [31]. LPS-treated rats that received an inter-
ventional acetate treatment showed a significant increase
in CD73 levels (by 67%) when compared to rats that re-
ceived water (Figure 3B) but demonstrated a significantly
Figure 1 Fourteen day prophylactic acetate supplementation alters CD73 levels, CD73 activity, and A2A receptor levels. Panel A shows
representative images of the western blot analysis for CD73, adenosine kinase (AK), A2A receptor (A2AR), and α-tubulin. Panel B and C show CD73
levels and CD73 activity, while Panel D and E show AK levels and A2AR levels, respectively. All values represent the means ± SD, n = 6, 12, 6 for
artificial cerebrospinal fluid (aCSF), lipopolysaccharide (LPS) and LPS + glyceryl triacetate (GTA) groups, respectively. Statistical significance set at
P ≤0.05 and the symbol ‘a’ represents a difference compared to the aCSF group and ‘b’ represents a difference compared to the LPS group.
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significant difference in AK levels between rats recei-
ving water and rats receiving acetate supplementation
(Figure 3D). Interventional acetate supplementation re-
sulted in a significant increase in A2A receptor levels
(155%) compared to controls (Figure 3E). These results
demonstrate that acetate supplementation is able to mo-
dulate CD73 and A2A receptor following an interventional
treatment strategy. While an increase in CD73 activity
was not correlated to an increase in CD73 protein levels
as seen with prophylactic treatment, it may be that the
mechanism by which acetate exerts its effects takes longer
to alter the activity of the enzyme.Discussion
Acetate supplementation elevates plasma acetate (appro-
ximately 19 mM) [19], brain acetate (approximately
11 mM) [36], and acetyl Co-A (approximately 9 μM)
levels [19]. This increase in brain acetyl-CoA metabolism
increases brain phosphocreatine levels and reduces AMP
levels, suggesting a potential role in altering brain purine
metabolism [26]. In order to integrate GTA-induced
changes in energy levels [26] with the potential to alter
purinergic metabolism, we investigated the effect that
acetate supplementation had on purinergic enzymes and
receptors in a rat model of neuroinflammation. These
studies suggest that acetate supplementation was able to
Figure 2 Twenty-eight day prophylactic acetate supplementation alters CD73 levels, CD73 activity, and adenosine kinase (AK) levels.
Panel A shows representative images of the western blot analysis for CD73, AK, A2A receptor (A2AR), and α-tubulin. Panel B and C show CD73
levels and CD73 activity, while Panel D and E show AK levels and A2AR levels, respectively. All values represent the means ± SD, n = 6, 12, 6 for
artificial cerebrospinal fluid (aCSF), lipopolysaccharide (LPS) and LPS + glyceryl triacetate (GTA) groups, respectively. Statistical significance is set at
P ≤0.05 and the symbol ‘a’ represents a difference compared to the aCSF group and ‘b’ represents a difference compared to the LPS group.
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kinase (AK), as well as the levels of the adenosine A2A re-
ceptor, which may describe a mechanism by which acetate
exerts its observed anti-inflammatory and potentially
neuroprotective effects. The premise that bioenergetic
stimulation can influence neuroinflammation has been
demonstrated in various animal models of Alzheimer’s
disease and Parkinson’s disease, as well as in Parkinson’s
disease patients [37]. Acetyl-L-carnitine, like acetate, bol-
sters mitochondrial metabolism in astrocytes and is neuro-
protective in a rat model of traumatic brain injury [38].
Similarly, the closest metabolic correlate of acetate sup-
plementation the ketogenic diet, also modulates brain
mitochondrial metabolism and is neuroprotective [39,40]through a mechanism involving adenosine [41]. With
14- and 28-day prophylactic acetate supplementation we
found that GTA was able to prevent LPS-induced reduc-
tion in CD73 levels in addition to increasing CD73 activity
(Figures 1 and 2). This suggests that GTA can increase
brain adenine nucleotide metabolism and potentially ele-
vate extracellular levels of adenosine. In this regard,
interferon-β used for treatment of multiple sclerosis also
increases the expression of CD73 [42,43]. Interventional
acetate supplementation increased CD73 levels however
lower CD73 activity was observed with GTA as compared
to the LPS group (Figure 3). Cortical stab wound and focal
cerebral ischemia models of brain injury have demon-
strated a biphasic alteration in CD73 expression and
Figure 3 Interventional acetate supplementation alters CD73 levels, CD73 activity, and A2A receptor levels. Rats were infused with
lipopolysaccharide (LPS) and were divided into two groups; beginning treatment with water or glyceryl triacetate (GTA) beginning on day 14.
Panel A shows representative images of the western blot analysis for CD73, AK, A2A receptor (A2AR), and α-tubulin. Panel B and C show CD73
levels and CD73 activity, while Panel D and E show adenosine kinase (AK) and A2AR levels, respectively. Data represent mean ± SD, n = 8, 6 for
LPS + H2O and LPS + GTA groups, respectively. The asterisk (*) represents statistical difference compared to LPS + H2O group (P ≤0.05).
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increase in expression and activity of CD73 during the
post-injury period [44-46]. Thus, this suggests that the
14 days of interventional GTA treatment may not be suffi-
cient to elevate CD73 activity. Although during CD73 ac-
tivity measurements, the non-specific phosphatase activity
was inhibited by β-glycerophosphate and the non-CD73
related nucleotidase activity was subtracted from samples
by AMCP, involvement of other alkaline phosphatases and
intracellular cellular nucleotidases that are not completely
inhibited by AMCP cannot be ruled out [47]. Furthermore,
different CD73 isoforms in distinct brain regions [47] have
been reported which may differentially contribute and
interfere with the whole brain CD73 activity analysis in the
current study.Another key enzyme that regulates extracellular levels of
adenosine is AK. Although intracellular, the low Km of AK
for adenosine (1.5-2.4 μM) [48] combined with the bidirec-
tional and equilibrative nature of adenosine transporters,
allows AK to control adenosine uptake. We found that
28 days of LPS-infusion increased AK levels as seen during
traumatic brain injury and epilepsy [15,49] (Figure 2). This
increase was prevented by the long-term prophylactic
treatment, which suggests that GTA in presence of LPS is
able to enhance extracellular adenosine availability by pre-
venting the increase in its uptake and conversion to AMP.
However, this may lead to a scenario where, elevated ad-
enosine levels become more susceptible to adenosine
deaminase mediated degradation to inosine. Since these al-
terations may be cell-type specific, an in depth in vitro
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comprehensive view of how acetate alters brain adenosine
metabolism.
Extracellular adenosine is an endogenous agonist for
four different G protein-coupled (A1, A2A, A2B, and A3)
receptors, of which the A1 and A2A receptors have the
greatest relevance in the central nervous system [50,51].
The A1 receptor signal cascade generally suppresses neur-
onal activity, inhibits synaptic transmission, and reduces
the activation and response of microglia [52,53]. Adeno-
sine A2A receptors, on the other hand are known to
mediate LPS-induced neuroinflammation and neuronal
dysfunction [9,10,54]. Antagonists of the A2A receptors
have been shown to be anti-inflammatory in a number of
CNS disorders [52,54-56], mainly secondary to their in-
hibitory effects on the glutamate outflow and resulting
excitotoxicity [9,10]. In specific regard to our model, it
was found that the A2A receptor inhibitor caffeine atte-
nuates LPS-induced neuroinflammation [55]. We found
that at 14 days, LPS-induced neuroinflammation caused a
significant increase in A2A receptor levels compared to
controls (Figure 1), in line with our previous findings that
show an increase in IL-1β expression [20], which is known
to increase A2A receptor levels [57]. Fourteen-day pro-
phylactic acetate supplementation prevented this LPS-
induced increase (Figure 1) in A2A receptors, which is in
agreement with results demonstrating that GTA atte-
nuates LPS-induced pro-inflammatory cytokine release
[20]. Since blockade of A2A receptor prevents IL-1β in-
duced exacerbation of neuronal toxicity [58], acetate sup-
plementation has a combined effect of reducing IL-1β
levels and A2A receptors that can offer robust neuropro-
tection by attenuating neuroinflammation. However, inter-
ventional acetate supplementation unlike the prophylactic
treatment increased A2A receptor levels (Figure 3). The
reason for this difference is not yet clear, but a bidirec-
tional effect of A2A receptors in neuroinflammation has
been described [59]. It is possible that 14 days of interven-
tional acetate supplementation started after significant in-
creases in neuroglia activation have already occurred may
not be sufficient to counteract the LPS-induced elevation
in A2A receptor levels. However, the ability of the A2A
receptors to control neuroinflammation is dependent on
local glutamate levels and is critical in determining whe-
ther their stimulation results in anti-inflammatory or pro-
inflammatory effects [59]. Distinct pathological stages
after injury respond to different A2A receptor modulators.
For example, during early spinal cord injury A2A receptor
agonists offer neuroprotection, while A2A receptor knock-
out was neuroprotective only during later injury stages
[60]. Thus, an alternative reasoning may be that the in-
crease in A2A receptors observed with interventional
GTA may be beneficial in enhancing the effects of
endogenous adenosine that may contribute towardsthe anti-inflammatory effect of acetate supplementation.
However, to make this determination a thorough investi-
gation of temporal changes in inflammatory markers, A2A
receptors, and local glutamate levels with LPS and GTA is
required. Further, the protective effects of adenosine A2A
receptor agonists and antagonists against spinal cord in-
jury are mediated through their effects in the periphery
and the CNS, respectively [11], hence it will be interesting
to study how GTA alters peripheral purinergic signaling.
A limitation of the interventional study was the lack of the
aCSF control group, which would have allowed us to de-
termine whether the increase in A2A receptors was indeed
an elevation from control levels. Thus, future studies that
examine the effect of interventional GTA strategy for
longer treatment duration with adequate controls are
necessary. Regardless, this study demonstrates that pro-
phylactic acetate supplementation does prevent the LPS-
induced increase in A2A receptor levels, which may help
to explain the mechanism by which GTA confers its anti-
inflammatory effects.
We previously reported that, acetate supplementation
increases histone acetylation [27] and reverses LPS-in-
duced histone H3 at lysine 9 (H3K9) hypoacetylation in a
model of neuroinflammation [20]. Histone hyperace-
tylation alters gene expression and also induces anti-
inflammatory effects [61,62]. Therefore, it is reasonable to
speculate that acetate induced histone acetylation may be
a potential underlying mechanism involved in the modula-
tion of adenosine metabolizing enzymes CD73 and AK as
well as the levels of the adenosine A2A receptors, espe-
cially at the level of gene transcription. Future studies will
determine the link between acetate-induced histone
acetylation changes and alteration in the levels of these
proteins. Using specific histone acetyltransferase inhibitors
to block the effect of acetate on histone acetylation will
allow us to determine its role in altering levels of adeno-
sine metabolizing enzymes and receptors. Further, by
studying if acetylated H3K9 is associated with the gene
promoters of adenosine metabolizing enzyme and recep-
tor will determine if acetate-induced alteration in their
expression is controlled by chromatin remodeling.
Conclusion
Since adenosine is a potent endogenous modulator of
neuronal activity and inflammation, development of thera-
peutic strategies that modulate adenosine metabolism may
offer treatment alternatives for neuroinflammation and
neurodegenerative disorders. This study attempts to iden-
tify the underlying mechanism of action and a treatment
regimen for glyceryl triacetate that has been shown to be
anti-inflammatory in rat models of neuroinflammation
and Lyme neuroborreliosis. In conclusion, both prophylac-
tic and interventional acetate supplementation can modu-
late adenosine metabolizing enzymes and A2A receptor
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http://www.jneuroinflammation.com/content/11/1/99levels supporting our hypothesis. Future experimentation
is needed to determine the specific brain regions, cell
types, and mechanisms involved in altering brain adeno-
sine metabolism with acetate supplementation.
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